A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CR, Kaltcheva T, Longmate J, Drake J, Slape C, Duarte L, Al Malki MM, Pullarkat VA, Aribi A, Devine S, Verneris MR, Miller JS, Forman SJ, Aldoss I, Diamond DJ.
Nakamura R, et al.
Haematologica. 2024 Jun 1;109(6):1994-1999. doi: 10.3324/haematol.2023.284544.
Haematologica. 2024.
PMID: 38328852
Free PMC article.
Clinical Trial.
No abstract available.